Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC's Dialectic and Philanthropic Societies celebrates 230 years of dialogue and debate
When you think of something that ties all Tar Heels together and has existed during every student’s time at the University of North Carolina, Old...
Sun Feb 1, 2026

An Award-Winning UNC English Professor Combines Basketball With Poetry
At the basketball courts near Cobb Residence Hall, Gabrielle Calvocoressi leads a group of students in a friendly shootaround. She’s wearing a Big Bird t-shirt...
Sat Jan 31, 2026

10 ways staff kept Carolina safe during the storm
While many of us make plans to hunker down the second we see that snowflake hit our weather apps, hundreds of employees at the University...
Fri Jan 30, 2026

The multigenerational experiences of being a Tar Heel
Some parents encourage their children to attend their alma mater, while others watch them find their own path to Chapel Hill. Either way, UNC draws...
Wed Jan 28, 2026